Aerovate Therapeutics (AVTE) Stock Chart & Stock Price History $7.03 -0.03 (-0.42%) As of 06/11/2025 Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aerovate Therapeutics Stock Price Performance The Aerovate Therapeutics (AVTE) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 99.13%, with a year-to-date return of -92.42%. In the past month, the stock has decreased 18.73%, reflecting recent market activity. As of the latest close, Aerovate Therapeutics traded at $7.06 with a market cap of $204.63 million and volume of 409,650 shares. Receive AVTE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+2.03%1 Month Performance-18.73%3 Month Performance-91.97%Year-To-Date Performance-92.42%1 Year Performance-99.13% AVTE Stock Chart for Thursday, June, 12, 2025 AVTE Chart by TradingView Aerovate Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/11/2025$7.71$7.06-8.43%$7.85$6.93409,650 shs$204.63 million06/10/2025$7.19$7.71+7.23%$8.45$7.27674,022 shs$223.47 million06/09/2025$7.19$7.19$7.72$6.79567,200 shs$208.40 million06/06/2025$7.21$6.89-4.44%$7.45$6.89143,861 shs$199.71 million06/05/2025$7.25$7.21-0.55%$8.01$7.12232,818 shs$208.98 million06/04/2025$7.20$7.25+0.69%$7.91$7.13390,996 shs$210.14 million06/03/2025$7.25$7.20-0.69%$7.50$7.02285,076 shs$208.69 million06/02/2025$7.25$7.25$7.40$6.88375,346 shs$210.14 million05/30/2025$7.25$7.09-2.21%$7.63$6.99372,015 shs$205.50 million05/29/2025$7.37$7.25-1.63%$7.61$7.09504,908 shs$210.14 million Get the Latest News and Ratings for AVTE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/28/2025$7.03$7.37+4.84%$7.64$6.98446,937 shs$213.62 million05/27/2025$7.03$7.03$7.44$6.71398,026 shs$203.77 million05/26/2025$7.03$7.03$7.44$6.71398,026 shs$203.77 million05/23/2025$7.49$7.32-2.27%$7.62$6.98226,035 shs$212.17 million05/22/2025$7.72$7.49-2.92%$7.83$7.30121,441 shs$217.10 million05/21/2025$7.42$7.72+3.98%$8.14$7.41285,101 shs$223.62 million05/20/2025$7.35$7.42+1.02%$7.64$7.05301,506 shs$215.07 million05/19/2025$7.35$7.35$7.59$7.11302,580 shs$212.90 million05/16/2025$7.55$7.40-1.99%$7.50$7.05271,381 shs$214.49 million05/15/2025$8.61$7.55-12.31%$8.66$7.4281,756 shs$218.84 million05/14/2025$8.58$8.61+0.35%$8.95$7.6981,973 shs$249.56 million05/13/2025$8.65$8.58-0.81%$9.31$8.20120,761 shs$248.69 million05/12/2025$8.65$8.65$9.40$8.4763,694 shs$250.72 million Related Companies Pharming Group Stock Chart Immunome Stock Chart ArriVent BioPharma Stock Chart Chimerix Stock Chart Avid Bioservices Stock Chart Gyre Therapeutics Stock Chart Cogent Biosciences Stock Chart Replimune Group Stock Chart Cronos Group Stock Chart Vir Biotechnology Stock Chart Receive AVTE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:AVTE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
